



## Online Supplementary Material

Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs. *JHEOR*. 2026;13(1):??-??. [doi:10.36469/jheor.2026.161191](https://doi.org/10.36469/jheor.2026.161191)

### **Table S1: Overall All-Cause Treatment Costs in Patients with Peripheral T-cell Lymphoma**

This supplementary material has been provided by the authors to give readers additional information about their work.



**Table S1.** Overall All-Cause Treatment Costs in Patients with Peripheral T-cell Lymphoma

Treatment Costs	Overall Treated (N = 649)	1LOT (N = 320)	2LOT (N = 168)	≥3LOT (N = 161)
Cost of hospitalizations PPPM (in ¥1000)				
n (%)	643 (99.1)	314 (98.1)	168 (100)	161 (100.0)
Mean (SD)	¥1687.4 (3370.5) \$10725.2 (21423.1)	¥1333.4 (2244.3) \$8475.2 (14264.9)	¥1948.2 (2889.0) \$12382.9 (18362.7)	¥2105.7 (5150.2) \$13384.0 (32735.0)
[Q1, Q3]	¥[225.7, 1902.6] \$[1434.6, 12093.1]	¥[130.0, 1603.9] \$[826.3, 10194.5]	¥[332.9, 2331.3] \$[2115.9, 14817.9]	¥[488.5, 2013.4] \$[3104.9, 12797.3]
Cost of ER visits (¥1000 PPPM)				
n (%)	217 (33.4)	76 (23.8)	74 (44.0)	67 (41.6)
Mean (SD)	¥730.9 (1153.3) \$4646.6 (7327.1)	¥947.4 (1451.1) \$6021.2 (9222.7)	¥689 (937.2) \$4377.2 (5956.9)	¥531.7 (944.9) \$3379.4 (6004.3)
[Q1, Q3]	¥[55.2, 871.8] \$[350.9, 5541.2]	¥[48.5, 1068.7] \$[308.3, 6792.7]	¥[42.6, 968.5] \$[270.8, 6155.9]	¥[64.8, 422.9] \$[411.9, 2688.0]
Cost of outpatient visits (¥1000 PPPM)				
n (%)	530 (81.7)	237 (74.1)	143 (85.1)	150 (93.2)
Mean (SD)	¥2044.4 (4872.3) \$12994.3 (30968.7)	¥1223.5 (2601.4) \$7776.6 (16534.7)	¥2362.9 (4973.7) \$15018.8 (31613.2)	¥3037.9 (6915.7) \$19309.1 (43956.7)
[Q1, Q3]	¥[175.3, 1715.5] \$[1114.2, 10903.8]	¥[131.3, 1123.0] \$[834.6, 7137.9]	¥[214.4, 2457.1] \$[1362.7, 15617.5]	¥[278.0, 2143.6] \$[1767.0, 13624.9]
Cost of prescription drugs <sup>a</sup> (¥1000 PPPM)				
n (%)	649 (100.0)	320 (100.0)	168 (100)	161 (100.0)
Mean (SD)	¥839.3 (3754.8) \$5334.6 (23865.8)	¥319.9 (1206.3) \$2033.3 (7667.3)	¥832.5 (3399.3) \$5291.4 (21606.2)	¥1878.5 (6364.9) \$11939.9 (40455.7)
[Q1, Q3]	¥[26.1, 305.1] \$[165.9, 1939.2]	¥[13.5, 97.0] \$[85.8, 616.5]	¥[36.9, 479.3] \$[234.5, 3046.5]	¥[88.1, 760.6] \$[560.0, 4834.4]
Cost of stem cell transplants (¥1000 PPPM)				
n (%)	44 (6.8)	3 (0.9)	15 (8.9)	26 (16.1)
Mean (SD)	¥36.8 (69.2) \$233.9 (439.8)	¥151.5 (255.7) \$962.9 (1625.2)	¥32.9 (31.3) \$209.1 (198.9)	¥25.8 (27.4) \$164.0 (174.2)
[Q1, Q3]	¥[7.9, 41.5] \$[50.2, 263.8]	¥[0.06, 446.7] \$[0.4, 2839.3]	¥[7.8, 46.5] \$[49.6, 295.6]	¥[10.1, 29.3] \$[64.2, 186.2]
Cost of drugs <sup>b</sup> (¥1000 PPPM)				
n (%)	649 (100.0)	320 (100.0)	168 (100)	161 (100.0)
Mean (SD)	¥2914.1 (5594.8) \$18522.2 (35560.9)	¥1797.7 (3003.7) \$11426.3 (19091.7)	¥3488.5 (5385.1) \$22173.1 (34228.1)	¥4533.6 (8546.1) \$28815.9 (54319.6)
[Q1, Q3]	¥[489.4, 2826.9] \$[3110.7, 17968.0]	¥[313.1, 1965.9] \$[1990.1, 12495.4]	¥[801.8, 4206.4] \$[5096.3, 26736.2]	¥[876.6, 3480.5] \$[5571.7, 22122.3]
Cost of labs (¥1000 PPPM)				
n (%)	647 (99.7)	318 (99.4)	168 (100)	161 (100.0)
Mean (SD)	¥49.2 (55.9) \$312.7 (355.3)	¥47.0 (64.8) \$298.7 (411.9)	¥55.2 (54.7) \$350.9 (347.7)	¥47.3 (33.2) \$300.6 (211.0)
[Q1, Q3]	¥[16.5, 63.4] \$[104.9, 403.0]	¥[12.3, 59.0] \$[78.2, 375.0]	¥[19.1, 73.1] \$[121.4, 464.6]	¥[24.0, 59.5] \$[152.5, 378.2]
Cost of total <sup>c</sup> healthcare PPPM (¥1000 PPPM)				
n (%)	649 (100.0)	320 (100.0)	168 (100)	161 (100.0)
Mean (SD)	¥3341.4 (5654.6) \$21238.2 (35941.0)	¥2214.5 (3167.1) \$14075.5 (20130.3)	¥3959.5 (5443.1) \$25166.8 (34596.7)	¥4936.0 (8548.4) \$31373.5 (54334.2)
[Q1, Q3]	¥[834.5, 3337.7] \$[5304.1, 21214.6]	¥[512.8, 2667.2] \$[3259.4, 16952.9]	¥[1175.1, 4726.5] \$[7469.0, 30042.0]	¥[1197.9, 4244.4] \$[7613.9, 26977.7]

**Table S1.** Overall All-Cause Treatment Costs in Patients with Peripheral T-cell Lymphoma

Treatment Costs	Overall Treated (N = 649)	1LOT (N = 320)	2LOT (N = 168)	≥3LOT (N = 161)
Cumulative <sup>d</sup> cost of PTCL-related healthcare per patient (¥1000)				
n (%)	649 (100.0)	320 (100.0)	168 (100)	161 (100.0)
Mean (SD)	¥62 323.9 (168 352.9)	¥28 267.1 (82 696.3)	¥65 456.2 (154 437.4)	¥126 736.6 (264 159.6)
	\$396 149.0 (1 070 209.6)	\$179 685.1 (525 594.3)	\$416 064.5 (981 650.9)	\$805 606.5 (1 679 065.0)
[Q1, Q3]	¥[6434.4, 44 950.2]	¥[3892.4, 19 476.8]	¥[10 208.7, 53 972.6]	¥[21 326.7, 96 124.4]
	[\$40 891.8, 285 671.2]	[\$24 739.0, 123 789.6]	[\$64 881.0, 342 967.1]	[\$135 547.6, 610 993.0]

Abbreviations: ER, emergency room; LOT, line of therapy; PPPM, per patient per month; Q, quartile; SD, standard deviation.

<sup>a</sup> Prescription drugs include drugs for PTCL-related anticancer treatments (excluding steroids).

<sup>b</sup> Drugs include all drugs including anticancer drugs.

<sup>c</sup> Total healthcare includes all healthcare utilization including hospitalizations, ER visits, outpatient visits, prescription drugs, stem cell transplants, prescription and non-prescription drugs, and labs.

<sup>d</sup> From diagnosis to end of follow-up.